Text Size

Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

This study has been completed.
Sponsor:
Collaborators:
Primorus Clinical Trials
National Multiple Sclerosis Society
Information provided by (Responsible Party):
Innate Therapeutics Limited
ClinicalTrials.gov Identifier:
NCT01191996
First received: August 30, 2010
Last updated: December 5, 2012
Last verified: December 2012
History of Changes
  Purpose

The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic progressive multiple sclerosis.


Condition Intervention Phase
Secondary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis
 Biological: MIS416
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Innate Therapeutics Limited:

Primary Outcome Measures:
  • Safety profile, including maximum tolerated dose [ Time Frame: 1 month in DE phase, 3 months in DC phase ] [ Designated as safety issue: Yes ]
    Dose-limiting toxicities, adverse events, safety MRI assessments


Secondary Outcome Measures:
  • Pharmacodynamic assessments [ Time Frame: 1 month in DE phase, 3 months in DC phase ] [ Designated as safety issue: Yes ]
    Serum and cellular immunological assays

  • MRI assessments [ Time Frame: 1 month in DE phase, 3 months in DC phase ] [ Designated as safety issue: Yes ]
    Safety MRIs

  • Clinical status [ Time Frame: 3 months in DC phase ] [ Designated as safety issue: No ]
    Neurological examination, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), Fatigue Severity Scale (FSS), Multiple Sclerosis Quality of Life (MSQLI).


Enrollment: 34
Study Start Date: August 2010
Study Completion Date: November 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MIS416
MIS416, immunomodulating microparticle, given intravenously weekly
 Biological: MIS416
MIS416 intravenously every week

Detailed Description:

This is a single center, open-label, non-randomized, dose-escalation study, to be conducted in two phases:

  • a dose-escalation (DE) phase, to evaluate the safety, tolerability, MTD, and PD of MIS416 administered IV once weekly for 4 doses; and
  • a dose-confirmation (DC) phase, which will be a cohort expansion at or below the MTD (i.e., the RTD) of MIS416, dosed once weekly for up to 12 doses.

Subjects will be treated with a weekly IV dose of MIS416 in 28-day cycles: 1 cycle in the DE phase, and up to 3 cycles in the DC phase. Subjects will be evaluated and dosed weekly each cycle in each phase. Subjects will return for a follow-up visit 7 days after completion of the last dose of study drug.

The primary objectives of this study are:

  1. To determine the safety and tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended therapeutic dose (RTD) of intravenously (IV) administered MIS416 weekly in patients with chronic progressive multiple sclerosis (CPMS); and
  2. To assess the pharmacodynamic (PD) effects of MIS416, including effects on serum cytokine levels and peripheral blood mononuclear cell (PBMC) composition, cytokine/chemokine expression and function.

The secondary objectives of this study are:

  1. To document any changes in MS clinical status occurring during the 12-week MIS416 dosing period in the dose-confirmation phase, as determined by the Multiple Sclerosis Functional Composite (MSFC), Fatigue Severity Scale (FSS), Short Form Health Survey (SF-36), and Expanded Disability Status Scale (EDSS); the frequency of clinical relapses; and signs of clinical activity on serial cranial MRI scans; and
  2. To evaluate, in exploratory fashion, any correlations between clinical, radiological and PD outcomes.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age.
  • Diagnosis of MS, by the McDonald criteria.
  • Chronic progressive MS (CPMS), defined as either primary progressive MS (PPMS) or secondary progressive MS (SPMS), per the criteria of the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. [NOTE: In the dose-confirmation phase, only subjects with SPMS may be enrolled].
  • MS is clinically active with worsening clinical status within the past 2 years, defined as an increase in EDSS by 1 point or more, sustained for at least 6 months.
  • Expanded Disability Status Scale (EDSS) of 2.5 to 7.0 at Screening.

  • The following laboratory values must be documented within 3 days prior to initiation of study drug:

    • Absolute neutrophil count (ANC) >= 1 x 109/L
    • Platelet count >= 100 x 109/L
    • Serum creatinine =< 1.5 mg/dL
    • AST (SGOT) and ALT (SGPT) =< 2 × upper limit of normal.
  • Provide written informed consent to participate.

Exclusion Criteria:

  • Relapsing-remitting MS or progressive-relapsing MS
  • Any immunomodulatory drug therapy or immunosuppressive therapy within the previous six months, or vaccine or systemic corticosteroids within the previous 60 days, prior to initiation of study drug.
  • Exposure to other experimental treatments currently under investigation in MS clinical trials, including alemtuzamab, rituximab, fingolimod, and clabribine.
  • A diagnosis or history of collagen vascular disease (including Sjögren's syndrome and systemic lupus erythematosus), anticardiolipin antibody syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), sarcoidosis, vasculitis, Bechet's syndrome and/or Lyme disease.
  • History of alcohol or drug abuse (with the exception of cannabinoids) within 2 years prior to initiation of study drug.
  • Previous exposure to MIS416.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01191996

Locations
New Zealand
Primorus Clinical Trials, 40 Stewart Street
Christchurch, Canterbury, New Zealand, 8011
Sponsors and Collaborators
Innate Therapeutics Limited
Primorus Clinical Trials
National Multiple Sclerosis Society
Investigators
Principal Investigator: Alison Luckey Primorus Clinical Trials
Principal Investigator: Tim Anderson Department of Medicine, University of Otago
  More Information

No publications provided

Responsible Party: Innate Therapeutics Limited
ClinicalTrials.gov Identifier: NCT01191996     History of Changes
Other Study ID Numbers: MIS416-201
Study First Received: August 30, 2010
Last Updated: December 5, 2012
Health Authority: New Zealand: Ministry of Health

Keywords provided by Innate Therapeutics Limited:
SPMS
PPMS
MS
Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Multiple Sclerosis, Chronic Progressive
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
 Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 22, 2013